We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Rheumatology

Journal Scan / Research · March 24, 2022

Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After ICI Therapy for Cancer

Arthritis & Rheumatology (Hoboken, N.J.)

 

Additional Info

Disclosure statements are available on the authors' profiles:

Arthritis & Rheumatology (Hoboken, N.J.)
Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer
Arthritis Rheumatol 2022 Mar 01;74(3)527-540, A Cunningham-Bussel, J Wang, LC Prisco, LW Martin, KMM Vanni, A Zaccardelli, M Nasrallah, L Gedmintas, LA MacFarlane, NA Shadick, MM Awad, O Rahma, NR LeBoeuf, EM Gravallese, JA Sparks

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading